42 results
8-K
EX-5.1
6wb2iliw4clfimh r4
1 Feb 24
Entry into a Material Definitive Agreement
4:09pm
424B3
zv7ome
4 Apr 23
Prospectus supplement
4:57pm
POS AM
jymbnk71nwhbgv
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
8-K
EX-99.1
2wqc4hbijwkjl5d73kmt
17 Nov 22
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
4:30pm
8-K
EX-5.1
ji5w6on35nrkr1bl
16 May 22
Entry into a Material Definitive Agreement
9:49pm
PRE 14A
l06odk
21 Apr 22
Preliminary proxy
4:33pm
S-8
EX-5.1
ndwhnqii5kvlajxd
15 Sep 21
Registration of securities for employees
4:55pm
424B4
z0xikhnfg1t3tvwn
17 Jun 21
Prospectus supplement with pricing info
4:31pm